Xvivo Perfusion AB (publ) reports Q2 results
Seeking Alpha ·
Xvivo Perfusion AB (publ) press release ( XVIPY ): Q2 Revenue of $239M. Thoracic sales increased by 53 percent in local currencies and by 52 percent excluding revenue from heart trials. Abdominal sales increased by 26 percent in local currencies.
DYAX Investor Sentiment
Bullish (Long) 49% · Bearish (Short) 51%
414 participants
Related News
- U.S. crude stockpiles fell 564K barrels last week, API says
- Why FormFactor (FORM) Stock Is Trading Up Today
- Tesla Stock Rises After Wave of Wall Street Target Hikes
- Apple Lawsuit Threatens OpenAI's Hardware Push as 400+ Ex-Apple Staff Join
- Elon Musk's Tesla Posts Best Quarter in Two Years
- 1844 Resources launches non‑brokered private placement to raise up to $1M